Engineering Inflammation-free CAR Therapy

Understanding how proteins impact inflammation associated with CAR-T cell therapies

Full Project Name:Engineering Inflammation-free CAR TherapyPrinciple Investigator:Subramaniam Malarkannan, PhD, MedicineCo-Investigator:Matthew J. Riese, MD, PhD, Medicine; Nirav Shah, MD, MedicineAward Amount:$200,000
Award Date
January2018
Project Duration:24 months

Project Description Narrative:


Treatment of refractory B cell malignancies, including B cell acute lymphoblastic leukemia (ALL), has been revolutionized with the development of therapies that make use of engineered T cells. However, inflammation is a major limitation in the use of CAR-T cells to treat cancers of B cell origin, in some instances resulting in organ malfunction and death. And inflammation associated with cytokine-release syndrome (CRS) caused by Chimeric Antigen Receptor transduced NK or T cell is a major limiting factor in the successful utilization of cellular immunotherapy for cancer.

Through this award, researchers will study unique signaling proteins that are exclusively responsible for regulating inflammation to support improved therapies for containing inflammation in cancer and other deleterious diseases such as autoimmune disorders.

Project Updates:


Project has not yet entered reporting period

AHW Logo

8701 W Watertown Plank Road,
Milwaukee, WI 53226-0509
(414) 955-4350

©2019 MEDICAL COLLEGE OF WISCONSIN. ALL RIGHTS RESERVED | MCW.EDU | TERMS & PRIVACY | NON-DISCRIMINATION NOTICE | CONTACT US

top